Skip to content
Screener

D&A at other companies

Eli Lilly logo
Eli LillyLLY
$534M+11.7%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$558K-11.7%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$212K-15.9%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$2.8M-3.9%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$1.91M-10.1%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$17K-87.3%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.17B+41.2%
Enterprise value$2.18B+31.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Biohaven’s 10-Q, filed May 4, 2026. Open the filing →

Filed
May 4, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001935979-26-000045

FAQ

What is Biohaven's D&A?
Biohaven (BHVN) reported D&A of $2.37M in Q1 2026.
How has Biohaven's D&A changed year-over-year?
Biohaven's D&A increased by 5.3% year-over-year, from $2.25M to $2.37M.
What is the long-term trend for Biohaven's D&A?
Over 3 years (2022 to 2025), Biohaven's D&A has grown at a 92.7% compound annual growth rate (CAGR), from $1.39M to $9.92M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Biohaven's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude